News & Investors

Want to stay updated? Subscribe to our newsletters. For free.

Have questions? Our live support would be happy to help you.

Year: 2011

Epigenomics AG Completes U.S. Clinical Validation Study for Colorectal Cancer Blood Test Epi proColon; Provides Update on U.S. Regulatory Plans

09.12.2011 | 111209_Epigenomics_AG_press_release_U.S._Clinical_Validation_Study Conference Call Scheduled for today, 9thDecember 2011 at 4 pm CET Berlin, Germany, and Seattle, WA, U.S.A. Epigenomics AG (Frankfurt Prime Standard: ECX), the cancer molecular diagnostic company, today reports the completion of the clinical validation study for its second-generation colorectal cancer blood test Epi proColon in the U.S. The study was […]

Read more

Epigenomics AG Completes U.S. Clinical Validation Study for Colorectal Cancer Blood Test Epi proColon; Provides Update on U.S. Regulatory Plans

PDF 79 KB   Berlin, Germany Epigenomics AG (ISIN: DE000A1K0516) reports the completion of the clinical validation study for its second-generation colorectal cancer blood test Epi proColon in the U.S. The study was designed to measure the clinical performance of Epi proColon for the detection of colorectal cancer in comparison to colonoscopy and is part […]

Read more

Epigenomics’ Licensee ARUP Presents Clinical Data for Colorectal Cancer Blood Test at AMP

Epigenomics to host a corporate workshop on advances in blood-based colorectal cancer screening; ARUP Laboratories will present independent data for its laboratory-developed Septin9 test 16.11.2011 | 111116_Epigenomics_press_release_AMP Grapevine, TX, U.S.A. – Epigenomics AG, the German-American cancer molecular diagnostics company, announced today that its licensing partner ARUP will be presenting recent study data for its laboratory-developed Septin9 […]

Read more

Epigenomics AG Announces Q3 Financial Results and Operational Highlights

09.11.2011 | Epigenomics_AG_press_release_Q3_Results Main focus for Q4: to successfully file PMA with the FDA in the U.S. and simultaneous re-launch in Europe with dramatically improved Epi proColon® 2.0 CE test Berlin, Germany, and Seattle, WA, U.S.A. Epigenomics AG (Frankfurt Prime Standard: ECX), the cancer molecular diagnostic company, today announced financial results for the third quarter and nine […]

Read more

Epigenomics announces the European launch of Epi proColon® 2.0 CE

25.10.2011 | 111025_EU_Launch_EN Presentation of the powerful second generation blood test for colorectal cancer screening during UEGW in Stockholm Berlin, Germany, and Stockholm, Sweden

Read more